Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
3.080
+0.070 (2.33%)
At close: Aug 7, 2026, 4:00 PM EDT
3.070
-0.010 (-0.32%)
After-hours: Aug 7, 2026, 7:53 PM EDT

Altimmune Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.040.040.020.43-0.074.41
Revenue Growth
80.00%105.00%-95.30%---46.12%
Gross Profit
0.040.040.020.43-0.074.41
Operating Income
-96.92-94.49-103.17-95.93-87.74-96.91
Net Income
-91.08-88.09-95.06-88.45-84.71-97.09
Earnings Per Share
-0.93-1.00-1.34-1.66-1.81-2.35
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
331.58273.5131.93197.86184.91190.34
Total Debt
34.5134.290000
Net Cash (Debt)
297.08239.21131.93197.86184.91190.34
Net Cash Growth
98.23%81.31%-33.32%7.00%-2.85%-11.87%
Net Cash Per Share
3.002.721.863.723.944.61

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-71.64-67.54-79.85-75.81-62.59-78.24
Capital Expenditures
-0.03-0.01--0.05-0.13-12.12
Free Cash Flow
-71.67-67.55-79.85-75.86-62.71-90.36
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-269217.00%-230461.00%-515860.00%-22518.50%129029.00%-2197.60%
Pretax Margin
-253002.78%-216521.95%-475295.00%-20762.21%124867.65%-2201.59%
Profit Margin
-253003.00%-214861.00%-475295.00%-20762.20%124578.00%-2201.59%
FCF Margin
-199081.00%-164746.00%-399240.00%-17806.80%92223.50%-2048.87%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-3.913.913.913.913.91
PS Ratio
16638.349763.0926083.101866.48-11902.0085.15